tiprankstipranks
Innovent Biologics (HK:1801)
:1801
Hong Kong Market
1801
Innovent Biologics
RESEARCH TOOLSreports
Want to see HK:1801 full AI Analyst Report?

Innovent Biologics (1801) Stock Forecast & Price Target

28 Followers
See the Price Targets and Ratings of:

1801 Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Innovent
Biologics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1801 Stock 12 Month Forecast

Average Price Target

HK$123.28
▲(34.73% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Innovent Biologics in the last 3 months. The average price target is HK$123.28 with a high forecast of HK$147.70 and a low forecast of HK$105.00. The average price target represents a 34.73% change from the last price of HK$91.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"75":"HK$75","148":"HK$148","93.25":"HK$93.3","111.5":"HK$111.5","129.75":"HK$129.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":147.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$147.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":123.277,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$123.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$105.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[75,93.25,111.5,129.75,148],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.6,84.83846153846153,90.07692307692307,95.3153846153846,100.55384615384614,105.79230769230767,111.03076923076922,116.26923076923076,121.5076923076923,126.74615384615383,131.98461538461538,137.22307692307692,142.46153846153845,{"y":147.7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.6,82.95976923076923,86.31953846153846,89.67930769230769,93.03907692307692,96.39884615384615,99.75861538461538,103.11838461538461,106.47815384615384,109.83792307692308,113.19769230769231,116.55746153846154,119.91723076923077,{"y":123.277,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.6,81.55384615384615,83.50769230769231,85.46153846153845,87.41538461538461,89.36923076923077,91.32307692307693,93.27692307692307,95.23076923076923,97.18461538461538,99.13846153846154,101.09230769230768,103.04615384615384,{"y":105,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":78.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.9,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$147.70Average Price TargetHK$123.28Lowest Price TargetHK$105.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UOB Kay Hian Analyst forecast on HK:1801
Unknown Analyst
UOB Kay Hian
Not Ranked
UOB Kay Hian
HK$112
Buy
22.40%
Upside
Reiterated
07/15/26
UOB Kay Hian Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
UBS Analyst forecast on HK:1801
Unknown Analyst
UBS
Not Ranked
UBS
HK$124→HK$124.1
Buy
35.63%
Upside
Reiterated
07/14/26
UBS Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
Zhongtai Securities Analyst forecast on HK:1801
Unknown Analyst
Zhongtai Securities
Not Ranked
Zhongtai Securities
HK$134.5
Buy
46.99%
Upside
Reiterated
07/10/26
Zhongtai Securities Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
HSBC Analyst forecast on HK:1801
Unknown Analyst
HSBC
Not Ranked
HSBC
HK$120
Buy
31.15%
Upside
Reiterated
07/10/26
HSBC Remains a Buy on Innovent Biologics (IVBXF)
Nomura Analyst forecast on HK:1801
Unknown Analyst
Nomura
Not Ranked
Nomura
HK$123.17
Buy
34.61%
Upside
Reiterated
07/09/26
Nomura Remains a Buy on Innovent Biologics (IVBXF)
CICC Analyst forecast on HK:1801
Unknown Analyst
CICC
Not Ranked
CICC
HK$118.3
Buy
29.29%
Upside
Reiterated
06/03/26
Innovent Biologics (IVBXF) Receives a Buy from CICC
BOCOM International Holdings Company Analyst forecast on HK:1801
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
HK$105
Buy
14.75%
Upside
Reiterated
06/03/26
Innovent Biologics (IVBXF) Gets a Buy from BOCOM International Holdings Company
CSC Financial Analyst forecast on HK:1801
Unknown Analyst
CSC Financial
Not Ranked
CSC Financial
HK$147.7
Buy
61.42%
Upside
Reiterated
06/02/26
CSC Financial Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
Morgan Stanley Analyst forecast on HK:1801
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
HK$135
Buy
47.54%
Upside
Reiterated
06/02/26
Morgan Stanley Keeps Their Buy Rating on Innovent Biologics (IVBXF)
J.P. Morgan Analyst forecast on HK:1801
Yang Huang
J.P. Morgan
J.P. Morgan
HK$111→HK$113
Buy
23.50%
Upside
Reiterated
04/30/26
J.P. Morgan Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
Shenwan Hongyuan Analyst forecast on HK:1801
Unknown Analyst
Shenwan Hongyuan
Not Ranked
Shenwan Hongyuan
HK$118.2
Buy
29.18%
Upside
Reiterated
04/14/26
Shenwan Hongyuan Remains a Buy on Innovent Biologics (IVBXF)
Guotai Haitong Analyst forecast on HK:1801
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
HK$107.4
Buy
17.38%
Upside
Reiterated
04/01/26
Guotai Haitong Remains a Buy on Innovent Biologics (IVBXF)
SDIC Securities Analyst forecast on HK:1801
Unknown Analyst
SDIC Securities
Not Ranked
SDIC Securities
HK$113.1
Buy
23.61%
Upside
Reiterated
04/01/26
SDIC Securities Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
Bank of China Analyst forecast on HK:1801
Unknown Analyst
Bank of China
Not Ranked
Bank of China
HK$118
Buy
28.96%
Upside
Reiterated
03/30/26
Bank of China Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
CMB International Securities Analyst forecast on HK:1801
Jill Wu
CMB International Securities
CMB International Securities
HK$113.86
Buy
24.44%
Upside
Reiterated
03/30/26
Analysts' Top Healthcare Picks: Xtant Medical Holdings (XTNT), Innovent Biologics (IVBXF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UOB Kay Hian Analyst forecast on HK:1801
Unknown Analyst
UOB Kay Hian
Not Ranked
UOB Kay Hian
HK$112
Buy
22.40%
Upside
Reiterated
07/15/26
UOB Kay Hian Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
UBS Analyst forecast on HK:1801
Unknown Analyst
UBS
Not Ranked
UBS
HK$124→HK$124.1
Buy
35.63%
Upside
Reiterated
07/14/26
UBS Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
Zhongtai Securities Analyst forecast on HK:1801
Unknown Analyst
Zhongtai Securities
Not Ranked
Zhongtai Securities
HK$134.5
Buy
46.99%
Upside
Reiterated
07/10/26
Zhongtai Securities Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
HSBC Analyst forecast on HK:1801
Unknown Analyst
HSBC
Not Ranked
HSBC
HK$120
Buy
31.15%
Upside
Reiterated
07/10/26
HSBC Remains a Buy on Innovent Biologics (IVBXF)
Nomura Analyst forecast on HK:1801
Unknown Analyst
Nomura
Not Ranked
Nomura
HK$123.17
Buy
34.61%
Upside
Reiterated
07/09/26
Nomura Remains a Buy on Innovent Biologics (IVBXF)
CICC Analyst forecast on HK:1801
Unknown Analyst
CICC
Not Ranked
CICC
HK$118.3
Buy
29.29%
Upside
Reiterated
06/03/26
Innovent Biologics (IVBXF) Receives a Buy from CICC
BOCOM International Holdings Company Analyst forecast on HK:1801
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
HK$105
Buy
14.75%
Upside
Reiterated
06/03/26
Innovent Biologics (IVBXF) Gets a Buy from BOCOM International Holdings Company
CSC Financial Analyst forecast on HK:1801
Unknown Analyst
CSC Financial
Not Ranked
CSC Financial
HK$147.7
Buy
61.42%
Upside
Reiterated
06/02/26
CSC Financial Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
Morgan Stanley Analyst forecast on HK:1801
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
HK$135
Buy
47.54%
Upside
Reiterated
06/02/26
Morgan Stanley Keeps Their Buy Rating on Innovent Biologics (IVBXF)
J.P. Morgan Analyst forecast on HK:1801
Yang Huang
J.P. Morgan
J.P. Morgan
HK$111→HK$113
Buy
23.50%
Upside
Reiterated
04/30/26
J.P. Morgan Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
Shenwan Hongyuan Analyst forecast on HK:1801
Unknown Analyst
Shenwan Hongyuan
Not Ranked
Shenwan Hongyuan
HK$118.2
Buy
29.18%
Upside
Reiterated
04/14/26
Shenwan Hongyuan Remains a Buy on Innovent Biologics (IVBXF)
Guotai Haitong Analyst forecast on HK:1801
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
HK$107.4
Buy
17.38%
Upside
Reiterated
04/01/26
Guotai Haitong Remains a Buy on Innovent Biologics (IVBXF)
SDIC Securities Analyst forecast on HK:1801
Unknown Analyst
SDIC Securities
Not Ranked
SDIC Securities
HK$113.1
Buy
23.61%
Upside
Reiterated
04/01/26
SDIC Securities Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
Bank of China Analyst forecast on HK:1801
Unknown Analyst
Bank of China
Not Ranked
Bank of China
HK$118
Buy
28.96%
Upside
Reiterated
03/30/26
Bank of China Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
CMB International Securities Analyst forecast on HK:1801
Jill Wu
CMB International Securities
CMB International Securities
HK$113.86
Buy
24.44%
Upside
Reiterated
03/30/26
Analysts' Top Healthcare Picks: Xtant Medical Holdings (XTNT), Innovent Biologics (IVBXF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ENOVEnovis
GKOSGlaukos
IMUXImmunic
AVTXAvalo Therapeutics
TARAProtara Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Innovent Biologics

3 Months
Jill WuCMB International Securities
Success Rate
8/13 ratings generated profit
62%
Average Return
+13.35%
Copying Jill Wu's trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +13.35% per trade.
1 Year
Jill WuCMB International Securities
Success Rate
9/13 ratings generated profit
69%
Average Return
+45.50%
Copying Jill Wu's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +45.50% per trade.
2 Years
Jialin ZhangNomura
Success Rate
12/14 ratings generated profit
86%
Average Return
+70.90%
Copying Jialin Zhang's trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +70.90% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1801 Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
6
7
9
10
10
Buy
11
15
12
8
8
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
22
21
18
18
In the current month, 1801 has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1801 average Analyst price target in the past 3 months is 123.28.
Each month's total comprises the sum of three months' worth of ratings.

1801 Financial Forecast

1801 Earnings Forecast

Next quarter’s earnings estimate for 1801 is HK$1.26 with a range of HK$1.26 to HK$1.26. The previous quarter’s EPS was -HK$0.01. 1801 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 1801 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1801 is HK$1.26 with a range of HK$1.26 to HK$1.26. The previous quarter’s EPS was -HK$0.01. 1801 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 1801 has Performed in-line its overall industry.

1801 Sales Forecast

Next quarter’s sales forecast for 1801 is HK$10.71B with a range of HK$10.53B to HK$10.89B. The previous quarter’s sales results were HK$7.76B. 1801 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 1801 has Performed in-line its overall industry.
Next quarter’s sales forecast for 1801 is HK$10.71B with a range of HK$10.53B to HK$10.89B. The previous quarter’s sales results were HK$7.76B. 1801 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 1801 has Performed in-line its overall industry.

1801 Stock Forecast FAQ

What is HK:1801’s average 12-month price target, according to analysts?
Based on analyst ratings, Innovent Biologics’s 12-month average price target is 123.28.
    What is HK:1801’s upside potential, based on the analysts’ average price target?
    Innovent Biologics has 34.73% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Innovent Biologics a Buy, Sell or Hold?
          Innovent Biologics has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Innovent Biologics’s share price target?
            The average share price target for Innovent Biologics is 123.28. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$147.70 ,and the lowest forecast is HK$105.00. The average share price target represents 34.73% Increase from the current price of HK$91.5.
              What do analysts say about Innovent Biologics?
              Innovent Biologics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of Innovent Biologics?
                To buy shares of HK:1801, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.